Premium
BENDAMUSTINE, RITUXIMAB, AND POLATUZUMAB VEDOTIN FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: SINGLE‐CENTER REAL‐WORLD EXPERIENCE
Author(s) -
Farina K. A,
Drill E,
Buie L. W,
Falchi L,
Kumar A,
Noy A,
Palomba M L,
Salles G,
Straus D. J,
Zelenetz A. D,
Buege M. J,
Batlevi C. L
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.87_2880
Subject(s) - bendamustine , medicine , rituximab , refractory (planetary science) , cohort , diffuse large b cell lymphoma , single center , surgery , salvage therapy , oncology , lymphoma , chemotherapy , physics , astrobiology